Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.58 |
| ▸ | RELA | Q04206 | 2/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL1185585 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL1184757 | 0.89 | CYP1A2 (0.60) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL4107771 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL9667822 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4358898 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL788729 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL1383868 | 0.82 | NPC1 (0.74) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL4107768 | 0.81 | NPC1 (0.62) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL14868333 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL14868344 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-7935694-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2010-12-30 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20060100194-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100194-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | SMN1; SMN2 2957/4885NPC1 2485/4885RAB9A 1640/4885 |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | SMN1; SMN2 2957/4885NPC1 2485/4885RAB9A 1640/4885 |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | SMN1; SMN2 2335/4885NPC1 2382/4885RAB9A 2128/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | SMN1; SMN2 2957/4885NPC1 2485/4885RAB9A 1640/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | SMN1; SMN2 2957/4885NPC1 2485/4885RAB9A 1640/4885 |
| US-20100331384-A1 | GUANIDINE BASED COMPOUNDS | ADRB2, ADRA2A, ADRA2C | SMN1; SMN2 1932/4885NPC1 3544/4885RAB9A 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.